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Comparison of the Abbott RealTime High-Risk Human
Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2
Assays to Direct Sequencing and Genotyping of HPV DNA
Yongjung Park,a Eunhee Lee,b Jonghyeon Choi,a Seri Jeong,a and Hyon-Suk Kima
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea,a and Green Cross Reference Laboratory, Yong In, Kyunggi-do,
Republic of Koreab
Infection with high-risk (HR) human papillomavirus (HPV) genotypes is an important risk factor for cervical cancers. We evalu-
ated the clinical performances of two new real-time PCR assays for detecting HRHPVs compared to that of the Hybrid Capture 2
test (HC2). A total of 356 cervical swab specimens, which had been examined for cervical cytology, were assayed by Abbott Real-
Time HR and Roche Cobas HPV as well as HC2. Sensitivities and specificities of these assays were determined based on the crite-
ria that concordant results among the three assays were regarded as true-positive or -negative and that the results of genotyping
and sequencing were considered true findings when the HPV assays presented discrepant results. The overall concordance rate
among the results for the three assays was 82.6%, and RealTime HR and Cobas HPV assays agreed with HC2 in 86.1% and 89.9%
of cases, respectively. The two real-time PCR assays agreed with each other for 89.6% of the samples, and the concordance rate
between themwas equal to or greater than 98.0% for detecting HPV type 16 or 18. HC2 demonstrated a sensitivity of 96.6%with
a specificity of 89.1% for detecting HRHPVs, while RealTime HR presented a sensitivity of 78.3%with a specificity of 99.2%. The
sensitivity and specificity of Cobas HPV for detecting HRHPVs were 91.7% and 97.0%. The new real-time PCR assays exhibited
lower sensitivities for detecting HRHPVs than that of HC2. Nevertheless, the newly introduced assays have an advantage of si-
multaneously identifying HPV types 16 and 18 from clinical samples.
Persistent cervical infection of human papillomavirus (HPV) isa well-known risk factor for developing cervical cancer, which
is the second most common malignancy in women, causing ap-
proximately 250,000 deaths each year worldwide (35, 36). More
than 150 HPV genotypes have been identified, and approximately
50 of them are known to infect cervical epithelia. Recently, the
International Agency for Research on Cancer (IARC) defined 12
high-risk (HR) HPV genotypes (HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, and 59) as group 1 carcinogens (3). In particular,
HPV16 is known as the most commonHPV type, contributing to
approximately half of all invasive cervical cancer cases. This geno-
type is also known to demonstrate a biological advantage in trans-
mission, persistence, and transformation (2). HPV18 has been
reported as the second most common cause of HPV-associated
invasive cervical cancers, and the proportion of cervical cancers
related to HPV16 and/or HPV18 has been reported to be between
68% and 82% (19).
Morphological examination of cervix cytology has beenused as
a screening test for the prevention and early detection of cervical
cancers over the past 50 years (12, 13). A major target of the cer-
vical screening is to detect cases of cervical intraepithelial neopla-
sia grade 3 (CIN3), which can be treated before it progresses to
invasive cancer. However, cytology tests are limited in predicting
HPV infections and cervical cancers. Abnormal findings in cervi-
cal cytology, i.e., atypical squamous cells of undetermined signif-
icance (ASCUS) or worse results, were present for only a quarter
of the patients who were infected with a single prevalent HRHPV
type (17). Meanwhile, the Bethesda system, which is widely used
to classify cervical cytology, can provide essential information on
the history of an HPV infection (22). For instance, a low-grade
squamous intraepithelial lesion (LSIL) would reflect microscopic
findings of acute HPV infections, and a high-grade squamous in-
traepithelial lesion (HSIL) could indicate the possibility of current
CIN3 or uncertain precancerous lesion (CIN2) (29). When the
Bethesda system was used to classify cytologic findings, approxi-
mately two-thirds of LSILs as well as the majority of HSILs were
associated with HR HPV types (6, 31).
Comparedwith changes in cervical cytology, HPVDNA can be
detected earlier and is identifiable for a longer time (30). Previous
randomized trials also reported the usefulness of HPV-based
screening tests in cervical screening programs (9, 28). Various
assays for detecting and genotyping HPV have been introduced.
Among them, the Hybrid Capture 2 HPV test (HC2) was the first
assay approved for detecting 13 HR HPVs by the U.S. Food and
Drug Administration (FDA), and the usefulness of this assay for
screening HPV infections has been extensively studied (1, 7, 14,
30). This assay also has been used as a reference test in many
studies to evaluate newly developed HPV detection assays (11, 21,
25–27, 32). HPV detection assays utilizing the real-time PCR
methodhave also been developed; these are able to produce results
for HPV types 16 and 18 and other HR genotypes at once (5, 15).
Among them, theAbbott RealTimeHRHPVassaywas introduced
to clinical laboratories, demonstrating performances comparable
with those of HC2 (4, 16, 24, 33). In April 2011, the Roche Cobas
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HPV assay, which also utilizes the real-time PCR principle, was
approved by the U.S. FDA for detecting HR HPVs, and a few
studies compared the results obtained byCobasHPVwith those of
HC2 (10, 20, 34). However, there are currently no published stud-
ies in the literature which concurrently evaluated HC2, RealTime
HR, and Cobas HPV assays.
In this study, we evaluated the performances of these three
assays for detecting HPV DNA using cervical swab specimens ob-
tained from Korean subjects for cytologic exam. We also com-
pared the results of the three tests with each other and with those
of genotyping using a liquid bead microarray (LBMA) as well as
direct sequencing.
MATERIALS AND METHODS
Samples. Cervical swab specimens, which were obtained for cytologic
exam,were collected from a total of 356women at SeveranceHospital and
Green Cross Reference Laboratory between August andOctober 2011. All
specimens were collected, placed in ThinPrep PreservCyt solution (Ho-
logic Inc.,Marlborough,MA), and stored at70°C until assayed forHPV
tests. All the specimens were classified into the four following groups
according to their cytologic results: normal (n 100), ASCUS (n 100),
LSIL (n 100), and HSIL (n 56). Nucleic acids from the samples were
prepared using cobas x 480 (Roche Molecular Diagnostics, Pleasanton,
CA), an automated instrument for nucleic acid extraction. Using 1 ml of
PreservCyt solution per subject, the instrument yielded 150 l of nucleic
acid eluted sample, and this sample was applied for detecting HPV DNA
using two real-time PCR assays as well as the HC2 HPV test (Qiagen
GmbH, Hilden, Germany).
Real-time PCR assays. Both the RealTime HR HPV assay (Abbott
Molecular Inc., Abbott Park, IL) and the Cobas HPV test (Roche Molec-
ular Diagnostics) utilize a mixture of multiple primers and probes for
amplifying and detecting human beta-globin gene from cervical cells, as a
target for internal quality control (QC), as well as HPV DNA from cervix
swab samples. The RealTime HR HPV test was performed using an
m2000rt automated analyzer (Abbott Molecular Inc.) for PCR amplifica-
tion and detection, and an assay cutoff of 32.0 for cycle threshold (CT) as
well as an internal QC target cutoff of 35.0 forCTwas used to interpret the
results. The CobasHPV assay was carried out using the cobas 4800 system
(Roche Molecular Diagnostics), comprising the cobas x 480 instrument
and the cobas z 480 analyzer, which are fully automated instruments for
nucleic acid preparation and real-time PCR, respectively. The results were
regarded as positive when the CT from a sample was less than 40.0.
The two real-time PCR assays are suggested by their respective man-
ufacturers to be able to detect 14 HR HPV genotypes (HPV types 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The results of the two
assays are reported as either positive or negative for HPV types 16 and 18
and a pooled result for the remaining 12 HR genotypes. All assay proce-
dures except preparation of nucleic acids, described above, were carried
out by following the manufacturers’ instructions. Both real-time PCR
assays also detect the aforementioned internal control target gene to en-
sure the quality of prepared nucleic acids. The preparation of nucleic acids
was carried out again when the assays did not detect the amplified internal
control gene.
HC2 HPV test. HC2 is a sandwich capture hybridization assay with
chemiluminescence using unlabeled single-stranded RNA probes (23).
After denaturation of nucleic acids, the single-stranded HPV DNA from
the specimen was hybridized with mixed RNA probes specific for 13 HR
HPVgenotypes (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and
68). RNA-DNA hybrids were captured on the surface of antibody-coated
microplates. Then, a solution containing alkaline phosphatase-conju-
gated antibody specific to RNA-DNA hybrids was added to the immobi-
lized hybrids. These hybrids were coupled with chemiluminescent sub-
strates, which were cleaved by alkaline phosphatase to produce light
signals. The emitted signals were measured as a ratio of relative light units
to cutoff (RLU/CO) using a luminometer. The samples with an RLU/CO
greater than or equal to 1.0 were regarded as positive.
Sequencing and genotyping. For the samples which showed discrep-
ant results among the three HPV detection assays, their HPV genotypes
were identified using PCR and sequencing. The following primers were
used for PCR: forward, TTT GTT ACT GTT GTR GAT ACY AC, and
reverse, GAA AAA TAA ACT GYA AAT CAW AYT C. After PCR ampli-
fication, the products were electrophoresed and the DNA of samples with
a positive band was purified. Sequencing PCR was performed using the
general primers GP5 and GP6, and the respective sequences of the HPV
DNA regions corresponding to the two primer sets were read using the
Applied Biosystems 3730xl DNA analyzer (Life Technologies Co., Carls-
bad, CA). Resulting DNA sequences were analyzed using the Basic Local
Alignment Search Tool (BLAST) database on the website of the NCBI to
confirm specific genotypes.
In addition, the same samples were assayed for genotyping using
GeneFinder HPV liquid beads microarray (LBMA) (Innomeditech Inc.,
Seoul, South Korea). This assay utilizes 5.6-mpolystyrenemicrospheres
(beads), which are internally dyed with specific intensities of red and
infrared fluorophores. Using different amounts of the two dyes for
batches of microspheres, microsphere sets with up to 100 different ad-
dresses can be formed. A microsphere for each address is attached with 1
among 32 kinds of oligonucleotides specific to respective genotypes of
HPV. The microspheres were reacted with HPV DNA, which had been
amplified during PCR, and were detected in a fluid stream using the Lu-
minex 200 system (Luminex Co., Austin, TX), so that HPV genotypes
were defined by the unique address of each microsphere.
SpecificHPVgenotypes concurrently detected by both direct sequenc-
ing and the liquid bead microarray were regarded as valid results, and
HPV genotypes were classified intoHR, low-risk (LR), and uncertain-risk
(UR) groups according to previously described criteria (8).
Data analysis. Analyse-it Method Evaluation Edition, version 2.22,
software (Analyse-it Software Ltd., Leeds, United Kingdom) was used for
all statistical analyses. Chi-square test was performed to compare propor-
tions of positive samples among the groups classified according to the
cytology results. Concordance rates and kappa coefficients (k) with 95%
confidence intervals (CIs) were calculated to estimate the concordance
between the results of the different assays. Sensitivities, specificities, and
95% CIs of the HC2 and the two real-time PCR assays were calculated
based on the diagnostic accuracy criteria, which were determined based
on the results of the genotyping and direct sequencing as well as those of
the HC2 and the two real-time PCR assays. When the results of the three
assays were all concordant, theywere regarded as true positive or negative,
whereas when there were discrepancies among the results by the three
assays, including the results for HPV types 16 and 18, the diagnostic ac-
curacy criteria were determined from the results of the HPV genotyping
using LBMA and direct sequencing, all of which were in agreement by
both methods. A P value less than 0.05 was considered to be significant.
RESULTS
Positive rates of HPV DNA. The positive rates of cervical HPV
DNA detected by HC2 and the two real-time PCR assays are sum-
marized in Table 1. For all three assays, positive rates were greater
for higher cytologic grades than for the lower grades (P  0.05),
except in the case of HPV 18 detected by the RealTime HR assay.
In all of the 356 samples, overall positive rates ranged from 27.0%
for the RealTime HR to 39.7% for the HC2, and HC2 produced
more positive results regardless of cytologic findings than the
other two assays. HPV16 was detected in more samples by Real-
Time HR in the groups with cytologic findings of ASCUS, LSIL,
andHSIL, while the positive rates ofHPV18were higher forCobas
HPV than for RealTime HR in the same cytology groups.
Concordance among the results for the HC2 and two real-
time PCR assays. Regardless of HPV genotype, the results for the
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three HPV detection assays agreed in 285 cases (82.6%) out of a
total of 345 samples tested by all the three assays. Discrepant re-
sults between the assays are presented in Table 2. Among the 24
samples which were positive byHC2 andCobasHPV but negative
by RealTimeHR, 19 (79.2%)were positive forHRHPV genotypes
upon sequencing and genotyping. Among the other 22 cases
which were positive only by HC2, 3 and 8 samples were positive,
respectively, for HR and LRHPVs by sequencing and genotyping,
but the other 6 specimens (27.3%) were negative according to
PCR for sequencing and genotyping. Most of the samples (6/7
[85.7%]) which were positive by HC2 and RealTime HR but neg-
ative byCobasHPVwere positive forHRHPVs by sequencing and
genotyping.
The concordance of the results of HC2 with those of the two
real-time PCR assays is displayed in Table 3. The results of Cobas
HPV agreed with those of HC2 in 89.9% of all samples (k 0.78),
and the results of RealTime HR corresponded with those of HC2
in 86.1% of the specimens (k  0.69). HC2 produced positive
results in 137, which was more than those for RealTime HR (93
positives) and Cobas HPV (114 positives).
Concordance between the results of the two real-time PCR
assays.Agreement between the results of the real-time PCR assays
according to the detected genotypes is summarized in Table 4.
Regardless of HPV genotype, the results of the RealTime HR and
Cobas HPV assays agreed in 89.6% of all cases (k 0.75). Among
the 8 samples with positive results only by RealTime HR, 6
(75.0%) were positive for HR genotypes by sequencing and geno-
typing, while 22 of 29 (75.9%) specimenswhichwere positive only
by Cobas HPVwere positive for HR genotypes by sequencing and
genotyping.
For the HPV16 genotype, the results of the two assays corre-
sponded well with each other (concordance rate, 98.0%; kappa
coefficient, 0.86). Among the specimens with discrepant results,
four were positive only by RealTime HR, and HPV16 was identi-
fied upon sequencing and genotyping in three (75.0%) of them,
whereas the three which were positive only by CobasHPVwere all
negative for HPV16 by sequencing and genotyping.
In addition, the two assays also produced good agreement for
HPV18 results, with a concordance rate of 99.2% and a kappa
coefficient of 0.87. RealTime HR showed no false-positive results
but one false-negative result for HPV18, while Cobas HPV pro-
duced no false-negative result but two false-positive results for
HPV18, compared to the results of sequencing and genotyping.
When considering the HR genotypes other than HPV types 16
and 18, the results of the two real-time PCR assays agreed with
each other at a rate of 89.9%, which is similar to the overall con-
TABLE 1 Positive rates of cervical HPV tested by different assays according to genotypes and cytologic resultsa
Assay HPV genotype
Positive rate (%) for samples with indicated cytology
P value
Normal
(n 100)
ASCUS
(n 100)
LSIL
(n 100)
HSIL
(n 56)
All
(n 356)
HC2b All detectable 6.3 30.2 52.0 92.7 39.7 0.0001
RealTime HR All detectable 3.0 23.0 30.0 71.4 27.0 0.0001
16 1.0 3.0 4.0 33.9 7.6 0.0001
18 0.0 2.0 4.0 7.1 2.8 0.0575
Other than 16 and 18 2.0 21.0 24.0 37.5 19.1 0.0001
Cobas HPV All detectable 2.0 27.0 41.0 83.9 32.9 0.0001
16 1.0 2.0 6.0 30.4 7.3 0.0001
18 0.0 2.0 5.0 10.7 3.7 0.0046
Other than 16 and 18 1.0 25.0 33.0 58.9 25.8 0.0001
a Abbreviations: ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion;
HC2, Hybrid Capture 2.
b Only 96, 96, 98, and 55 (a total of 345) samples with cytologic results of normal, ASCUS, LSIL, and HSIL, respectively, were assayed by HC2 due to sample quantities.
TABLE 2 Concordance among the results for the three assays for any detectable HPV genotypea
HC2 result
RealTime HR
result
Cobas HPV
result n (%) (total 356) Results for sequencing and genotyping (n)
Negative Negative Negative 201 (56.5) NT
Positive Positive Positive 84 (23.6) NT
Positive Negative Positive 24 (6.7) 18 (1),HR (18), LR(2), UR (2), negative (1)
Positive Negative Negative 22 (6.2) OHR (3), LR (8), UR (5), negative (6)
Positive Positive Negative 7 (2.0) 16 (2),HR (4), LR (1)
Negative Negative Positive 5 (1.4) HR (2),OHR (1), negative (2)
Negative Positive Positive 1 (0.3) 16 (1)
Negative Positive Negative 1 (0.3) Negative (1)
NT Negative Negative 8 (2.2) OHR (1), LR (1), negative (6)
NT Positive Positive 3 (0.8) HR (3)
a Positive findings are indicated by bold type. HR includes HPV genotypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. OHR indicates HPV genotypes 61, 62, 67, and 72. LR
represents HPV genotypes 3, 6, 10, 11, 27, 30, 32, 34, 40, 42, 43, 44, 53, 55, 69, and 73. UR corresponds with HPV genotypes 26, 54, 57, 70, 71, 74, 81, 83, 84, 86, 90, and 97.
Abbreviations: HC2, Hybrid Capture 2; NT, not tested; HR, high-risk genotypes which can be detected with the assays; LR, low-risk genotypes; UR, genotypes of uncertain risk;
OHR, other high-risk genotypes which are not included in the genotypes detectable by the three assays.
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cordance rate between the two assays, regardless of genotype. Co-
bas HPV also produced 30 more positive results for the HR geno-
types other thanHPV types 16 and 18. Among these specimens, 20
(66.7%) and 25 (83.3%) showed positive results for HR genotypes
other thanHPV type 16 or 18 and for any detectableHR genotype,
respectively. On the other hand, 6 were positive for HR genotypes
other than HPV types 16 and 18 only by RealTime HR, and 4
(66.6%) of themwere positive forHR genotypes upon sequencing
and genotyping.
Sensitivities and specificities of the HPV detection assays.
When the agreeing results between the assays and the results of
sequencing and genotyping were regarded as true findings for the
detection of HPV DNA, HC2 showed the highest sensitivity
(96.6%) but the lowest specificity (89.1%) for detectingHRHPVs,
among the three assays (Table 5). On the other hand, RealTime
HR showed the lowest sensitivity (78.3%) and the highest speci-
ficity (99.2%) for the detection of HR HPVs. The sensitivity and
specificity of CobasHPV forHRHPVswere 91.7% and 97.0% and
were between those of the other two assays. In addition, RealTime
HR showed higher sensitivity for HPV16 (100.0%) than Cobas
HPV (88.5%), while Cobas HPV demonstrated higher sensitivity
forHPV18 (100.0%) than RealTimeHR (90.9%). The specificities
of the two real-time PCR assays for detectingHPV types 16 and 18
were all above 99.0%.
The sensitivity and specificity ofHC2 for predicting cytology of
HSIL were 92.7% (95% CI, 82.4% to 98.0%) and 70.3% (95% CI,
64.7% to 75.5%), and those of RealTimeHRwere 71.4% (95%CI,
57.8% to 82.7%) and 81.3% (95% CI, 76.5% to 85.6%). Cobas
HPV showed a sensitivity of 83.9% (95%CI, 71.7% to 92.4%) and a
specificity of 76.7% (95%CI, 74.5% to 81.3%) for detecting HSIL.
Detection of coinfection with different HPV genotypes. The
two real-time PCRs are able to produce specified results for HPV
types 16 and 18 and the pool of the other 12 HR HPVs at once;
thus, coinfections with HPV types 16 and 18 and other HR HPVs
can be detected. As a result, coinfection was detected in 0.0% to
16.1% of the cases according to the different cytologic results (Ta-
ble 6). Overall, the Cobas HPV assay produced more positive re-
sults for coinfection than RealTime HR.
TABLE 3 Concordance of the results between the Hybrid Capture 2 assay and the other real-time PCR assaysa
Comparative assay Result
HC2 result (n)
Total (n)
Concordance
rate (%)
Kappa
coefficientb 95% CI
Positive
(n 137)
Negative
(n 208)
RealTime HR Positive 91 2 93 86.1 0.69 0.62–0.77
Negative 46 206 252
Cobas HPV Positive 108 6 114 89.9 0.78 0.71–0.85
Negative 29 202 231
a Abbreviations: HC2, Hybrid Capture 2; CI, confidence interval.
b All P values for the kappa coefficients were less than 0.0001.
TABLE 4 Concordance between the results of the two real-time PCR HPV detection assays according to HPV genotype
HPV genotype
RealTime HR
result
No. of specimens with
Cobas HPV result
Total (n)
Concordance
rate (%)
Kappa
coefficientb 95% CIaPositive Negative
All detectable Positive 88 8c 96 89.6 0.75 0.68–0.83
Negative 29d 231 260
Total 117 239 356
16 Positive 23 4e 27 98.0 0.86 0.75–0.96
Negative 3f 326 329
Total 26 330 356
18 Positive 10 0 10 99.2 0.87 0.71–1.02
Negative 3g 343 346
Total 13 343 356
Other than 16
and 18
Positive 62 6h 68 89.9 0.71 0.62–0.80
Negative 30i 258 288
Total 92 264 356
a CI, confidence interval. See Table 2 for HR, OHR, LR, and UR. In the footnotes which follow, positive findings are indicated by bold type.
b All P values for the kappa coefficients were less than 0.0001.
c Genotyping results (n): 16 (2),HR (4), LR (1), and negative (1).
d Genotyping results (n): 18 (1),HR (20),OHR (1), LR (2), UR (2), and negative (3).
e Genotyping results (n): 16 (3) and HR (1).
f Genotyping results (n): HR (1) and UR (2).
g Genotyping results (n): 18 (1) and HR (2).
h Genotyping results (n):HR (4), LR (1), and negative (1).
i Genotyping results: 16 (4), 18 (1),HR (19), OHR (1), LR (2), and negative (3).
Park et al.
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DISCUSSION
In this study, we compared the performances of two recently in-
troduced real-time PCR assays for detecting HR HPVs with those
of HC2. Accordingly, the positive rates of HPV DNA increased
according to the grades of cervical cytology. Particularly, all three
assays detected HR HPVs from HSIL samples in approximately
71% to 93% of cases, concurring with previous studies (6, 31).
However, the positive rates of HPV detected in our data varied
according to the assays, and HC2 produced more positive results
for HR HPVs than the other two assays regardless of cytology
results. There also was a significant number of discrepant results
between the assays, and the concordance rate between the results
for HC2 and the two real-time PCR assays ranged roughly from
86% to 90%, with kappa coefficients of 0.69 to 0.78. Thus, we
performed genotyping using LBMA and direct sequencing to re-
solve the discrepancies. HC2 showed the highest sensitivity
(96.6%) for detecting HRHPVs but the lowest specificity (89.1%)
(Table 5). On the other hand, the RealTime HR assay presented
the lowest sensitivity (78.3%) and the highest specificity (99.2%).
Similarly, HC2 also presented a slightly better sensitivity (97.6%)
and specificity (92.6%) than did the RealTime HR assay (sensitiv-
ity, 96.4%; specificity, 92.3%), with a concordance rate of 96.5%
(k  0.86) between the two assays in a previous study (4). In
contrast to these results, RealTime HR showed better sensitivities
(93.1% to 100.0%) for the detection of HR HPVs or CIN2 and
worse-grade CINs than HC2 (88.2% to 97.4%) in other previous
studies (16, 24, 33). In one other study, the accuracy for detection
of HR HPVs was also significantly higher with the Abbott Real-
Time HR (98.7%) than with HC2 (92.9%) (15).
In addition, the Cobas HPV test demonstrated a sensitivity
(91.7%) and specificity (97.0%) between those of the other two
assays. In recently published studies, Cobas HPV also showed
comparable performances to HC2, with kappa coefficients from
0.69 to 0.87, but there also were discrepant results between HC2
and Cobas HPV in approximately 6% to 15% of the samples (10,
20, 34). In another recent study, Cobas HPV showed a clinical
sensitivity of 89.7% and a specificity of 66.7% for detecting cases
with CIN2 or worse-grade CINs, whereas HC2 demonstrated a
better clinical sensitivity of 93.1% and a specificity of 72.2% (18).
Differences in concordance rates between the HPV detection as-
says among the studies might result from differences in the ana-
lytical sensitivities for different HPV genotypes and differences in
HPV genotypes among the constituent of subjects with HPV in-
fections. In the detection of HPV types 16 and 18, the results of
two real-time PCR assays presented good agreement with each
other in 98.0% or more of the samples. Therefore, the discrepan-
cies among the results for the three assays could have been caused
by differences in the analytical sensitivity for detecting HR HPVs
other than HPV types 16 and 18.
In our study, HC2 produced more positive results than the
other two real-time PCR assays, and there were 60 cases in which
the results of HC2 were discrepant with those of the other two
assays. Among the discrepant cases, HC2 presented 25 false-pos-
itive results with the median RLU/CO of 2.8 and 28 true-positive
cases with that of 45.6. Therefore, weakly positive results with a
low RLU/CO for HC2 could be falsely positive and would need to
be retested with other assays when clinical findings and results of
cervical cytology exam do not correspond with the result of HC2.
However, true- and false-negative cases were not able to be dis-
criminated by their RLU/CO alone.
Regarding HPV 16 detected by the two real-time PCR assays,
there were 7 discrepant results between the two assays (Table 4).
Three of themwere true positive for HPV16, and those three were
also positive by RealTimeHR (CTs 24.6, 24.9, and 25.8; cutoff
32.0) but negative by Cobas HPV. The other three were true neg-
ative, but Cobas HPV reported false-positive results with CTs
TABLE 5 Sensitivities and specificities of the HPV detection assays for high-risk genotypesa
Assay HPV genotype Sensitivity (%) 95% CI (%) Specificity (%) 95% CI (%)
HC2 All HR 96.6 91.4–99.1 89.1 84.3–92.8
RealTime HR All HR 78.3 69.9–85.3 99.2 97.0–99.9
16 100.0 86.8–100.0 99.7 98.3–100.0
18 90.9 58.7–99.8 100.0 98.9–100.0
Cobas HPV All HR 91.7 85.2–95.9 97.0 94.0–98.8
16 88.5 69.8–97.6 99.1 97.4–99.8
18 100.0 71.5–100.0 99.4 97.9–99.9
a Abbreviations: CI, confidence interval; HC2, Hybrid Capture 2; HR, high risk.
TABLE 6 Detection of coinfection with different HPV genotypes according to the assays and cervical cytology resultsa
Cytology (n)
Cases positive for HPV DNA
[n (%)] HPV coinfection [n (%)] Coinfection rateb (%)
RealTime HR Cobas HPV RealTime HR Cobas HPV RealTime HR Cobas HPV
Normal (100) 3 (3.0) 2 (2.0) 0 (0.0) 0 (0.0) 0.0 0.0
ASCUS (100) 23 (23.0) 27 (27.0) 3 (3.0) 2 (2.0) 13.0 7.4
LSIL (100) 30 (30.0) 41 (41.0) 2 (2.0) 3 (3.0) 6.7 7.3
HSIL (56) 40 (71.4) 47 (83.9) 4 (7.1) 9 (16.1) 10.0 19.1
All (356) 96 (27.0) 117 (32.9) 9 (2.5) 14 (3.9) 9.4 12.0
a Abbreviations: ASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
b Coinfection rate was calculated by dividing the number of coinfection cases by the number of cases positive for HPV DNA detected by the respective assays.
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around the cutoffCT of 40.0, except for one with aCT of 28.7. The
remaining one case was true negative, but RealTime HR reported
a false-positive result with aCT of 31.0. Thus, RealTime HR seems
to have better sensitivity and similar specificity for detecting HPV
16 compared to Cobas HPV (Table 5), and the results with CTs
near 40.0 forCobasHPV could have been false positive. In the case
of HPV18, results for the two real-time PCR assays agreed well
with each other, and there were only three discrepant results. Two
of the three were true negative for HPV18, but Cobas HPV re-
ported false-positive results with CTs of 36.1 and 38.1. Another
sample was true positive, and the result for this sample on Cobas
HPV was positive, with a CT of 27.0, but RealTime HR showed
false-negative results for the same case. Therefore, Cobas HPV
could have better sensitivity for detecting HPV18, while RealTime
HR might have better specificity.
In addition, there were 36 (10.1% of all 356 cases) discordant
results between the two real-time assays for HR HPV other than
HPV types 16 and 18. Among the 36 cases, 24 were true positive
upon sequencing and genotyping, while only 20 and 4 of them
were positive by Cobas HPV (median CT of 33.2) and RealTime
HR (medianCTof 27.8), respectively. The remaining 12 caseswere
true negative, but RealTime HR and Cobas HPV showed false-
positive results in 2 (median CT of 30.2; cutoff  32.0) and 10
(median CT of 37.7; cutoff  40.0) cases, respectively. Thus, CTs
around 30.0 for RealTime HR and 38.0 for Cobas HPV also could
be false positive. Particularly, the cutoff CT of Cobas HPV might
need to be adjusted to an optimal value in order to reduce false-
positive results while retaining its sensitivity, because this assay
produced more false-positive results in detecting HR HPVs re-
gardless of genotype.
Considering the cost-effectiveness and the sample quantity, we
unified the methods for nucleic acid preparation. Thus, the nu-
cleic acid preparations for HC2 and RealTime HR assays were
performed against the recommendations of the respective manu-
facturers, and this might produce biased results. However, both
real-time PCR assays also amplify human beta-globin gene from
cervical cells as the internal control to ensure the quality of the
DNA preparation, and we repeated the whole assay procedures,
including the nucleic acid preparation, when the internal control
was negative. Therefore, the DNA preparation step used in our
evaluation might not have significantly influenced our results.
In conclusion,HC2 showed the highest sensitivity for detecting
HR HPVs, and RealTime HR and Cobas HPV demonstrated
higher specificities than HC2. There were discrepancies among
the results for HR HPVs by the three assays in a significant pro-
portion of samples, and these discrepancies arose mainly in the
samples positive for HR HPVs other than HPV types 16 and 18.
The two real-time PCR assays presented good agreement with
each other for detecting HPV types 16 and 18, although the sensi-
tivities and specificities for detecting HPV type 16 or 18 were dif-
ferent between the two real-time PCR assays. These differences
could result from the small number of samples which were posi-
tive for HPV type 16 or 18. The clinical utility of the newly intro-
duced real-time assays would need to be further evaluated. Nev-
ertheless, they have an advantage of identifying HPV types 16 and
18 simultaneously from clinical samples.
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